Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab ...

Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and ...

Across the Phase 3 ROCKET program including ASCEND, the incidence of gastrointestinal ulceration events with rocatinlimab to date is less than 1 per 100 patient-years. The ASCEND study is ongoing and ...

A mgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational ...

Results from the Phase III ASCEND trial (NCT05882877) showed rocatinlimab maintained long-term efficacy with a favorable ...

Findings showed 16.4% of patients treated with rocatinlimab achieved rIGA success compared with 4.9% of patients who received placebo. Topline results were announced from a phase 3 trial evaluating ...

Please provide your email address to receive an email when new articles are posted on . 32.8% of rocatinlimab-treated patients achieved the co-primary endpoint of EASI 75 by week 24. 19.3% reached the ...

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects ...

Amgen & Kyowa Kirin announce positive results from rocatinlimab phase 3 ASCEND study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Wednesday, Sept ...